Depressive Disorders Biomarkers Market Size (2023-2030)

The Global Depressive Disorders Biomarkers Market was estimated to be worth USD 14.3 Million in 2022 and is anticipated to reach a value of USD 17.84 Million by 2030, growing at a fast CAGR of 2.8% during the forecast period 2023-2030.

Depressive disorders are clinical depression or mental health illnesses characterized by persistent feelings of hopelessness, boredom, sadness, and other moods. The person witnesses fluctuations in mood that impact the person’s daily functioning and performance. Some of the key symptoms of depressive disorders include depressive mood, changes in appetite and weight, lack of energy, fatigue, difficulty in making decisions, agitation, and frustration. Therefore, using biomarkers can help cure these disorders and improve the overall quality of life. Biomarkers, typically are biological measures that can indicate the presence, absence, and level of depression. However, there are no established biomarkers for depression, researchers are constantly making efforts to investigate the benefits and mechanisms of biomarkers for depression. Some of the markers studied by researchers include neuroimaging that measures the imbalances in the neurochemical functioning of the body and provide insights to healthcare practitioners. Another marker includes a genetic marker that analyzes the contribution of genes in developing depressive disorder in individuals and provides insights for further treatment. Furthermore, increased demand for personalized and advanced treatment for psychological illness contributes to the demand for biomarkers in the market.

Global Depressive Disorders Biomarkers Market Drivers:

An increase in depression drives the demand for depressive disorder biomarkers in the market.

The growing prevalence of depression due to hectic lifestyles, increased stress levels, social isolation, and others contributes to depressive disorders. Moreover, As per WHO (World Health Organization), 3.8% of the population experience depression of which 6% depression is common among women and 4% among men. Additionally, severe depression can also lead to suicide. Therefore, individuals are seeking personalized alternatives such as biomarkers that help to diagnose and monitor levels of depression and aid in monitoring the effect of biomarkers in the body. Moreover, biomarkers can provide objective insights into depression and aid in clinical assessments of the patient, thereby improving diagnostic accuracy. In addition, public awareness about mental health has further increased the demand for depressive disorder biomarkers in the market.

Technological advancements drive the demand for depressive disorder biomarkers in the market.

Technology plays a significant role in medical science and technology that contributes to the demand for depressive disorder biomarkers in the market. Advancements such as advanced imaging techniques such as PET (Position Emission Tomography), DTI (Diffusion Tensor Imaging), and others have aided in recognizing neurobiological depressive disorders. They have enabled healthcare professionals and researchers to examine the structure, function, and patterns in the brain and identify the biomarkers associated with depression. Furthermore, advancements in genomics such as high-throughput DNA sequencing technologies have made it possible to analyze genomic data and identify genetic variations causing depressive disorders. Apart from this, the emergence of wearable technologies has enabled individuals and healthcare professionals to monitor heart rate, physical activity, and sleep patterns, and identify objective biomarkers associated with depressive disorders. Further, the infusion of AI and data analytics have provided predictive models and patterns that help in identifying biomarkers for depressive disorders and developing diagnostic tools. Additionally, AI algorithms help in monitoring depression symptoms, predicting treatment responses, and providing data-driven personalized insights for depression management.

Global Depressive Disorders Biomarkers Market Challenges:

Stigma related to mental health and lack of consensus for diagnostic criteria can hinder the growth of biomarkers for depressive disorder in the market. Many people, hold a narrow mindset regarding mental health and are reluctant to diagnose or treat themselves, which can reduce the usage of biomarkers in the market.

Global Depressive Disorder Biomarkers Market Opportunities:

The Global Depressive Disorder Biomarker Market is anticipated to deliver lucrative opportunities for businesses, which include acquisitions, partnerships, collaborations, product launches, and agreements during the forecasted period. Furthermore, the increased prevalence of depression is predicted to develop the market for Metaverse in Education and enhance its future growth opportunities.

COVID-19 Impact on the Global Depressive Disorders Biomarkers Market:

The pandemic had a significant impact on the depressive disorder biomarkers market. Due to the pandemic, there was an increase in stress and anxiety on account of virus mutation and health concerns, which increased the rate of depression and boosted the market demand for depressive disorder biomarkers. However, due to travel restrictions and social distancing norms, there was a reduction in access to in-person healthcare services, which declined the demand for biomarkers. However, this was offset during the second phase of the pandemic on account of emerging telehealth solutions and remote monitoring solutions for patients.

Global Depressive Disorders Biomarkers Market Recent Developments:

In October 2021, Sonde Health launched a voice biomarker to monitor the mental health and well-being of individuals. The biomarker used a voice sample to evaluate mental well-being and serve as a warning system for depression and other mental health problems.

DEPRESSIVE DISORDERS BIOMARKERS MARKET REPORT COVERAGE:

Global Depressive Disorders Biomarkers Market Segmentation: By Type of Biomarkers

• Neurotransmitter Biomarkers

• Genetic Biomarkers

• Imaging Biomarkers

• Others

Based on market segmentation by type of biomarkers, neurotransmitter biomarkers occupy the highest share in the market.  Imbalances in the neurochemical functioning of the body are analyzed using neurotransmitter biomarkers. They measure the imbalances or dysregulation of neurotransmitters such as dopamine, serotonin, and norepinephrine for depressive disorders by collecting blood, urine, or cerebrospinal fluid samples. Moreover, they provide insights into the neurotransmitter mechanisms and help in identifying specific imbalances in individuals.

The imaging biomarkers segment is the fastest-growing segment during the forecast period. These include the use of neuroimaging techniques such as MRI, DTI, and PET for providing insights into the structure and patterns in the brain and analyze the presence of depressive disorder. Further, imaging biomarkers perform quantitative analysis of the brain to identify structural or functional abnormalities in the brain and recommend required treatments. Furthermore, these biomarkers are of great use to researchers as it helps them to understand the neural issues associated with depression and aid in predicting treatment response for the same.

Global Depressive Disorders Biomarkers Market Segmentation: By End-User

• Hospitals and Clinics

• Pharmaceuticals

• Research Institutes & Laboratories

Based on market segmentation by end-user, hospitals, and clinics occupy the highest share of the market. Biomarkers are used in hospitals and clinics to diagnose and treat depressive disorders in patients. They help in providing objective insights that can support the clinical assessment of the disorder and thereby improve diagnostic accuracy. Moreover, they also help in treatment selection by identifying patients’ responses to clinical interventions. In addition, they are widely used to monitor treatment effectiveness and recommend changes if needed.

The pharmaceuticals segment is the fastest-growing segment during the forecast period. Biomarkers in pharmaceuticals aid in developing treatments for depressive disorders. They help in identifying patient treatment responses and enable targeted clinical trials that can help in the development of future diagnostics.

Global Depressive Disorders Biomarkers Market Segmentation: By Diseases

• Bipolar Disorder

• Postpartum Depression

• Major Depressive Disorder

• Persistent Depressive Disorder

• Others

Based on market segmentation by diseases, major depressive disorder occupies the highest share in the market. It is the most common type of depressive disorder that lasts for two weeks, however, it has some common symptoms that can damage the daily mental functioning of an individual. These include depressive moods, insomnia, fatigue, cognitive slowdown, uncontrolled aggression, and others. Biomarkers used for treating major depressive disorder include genetic biomarkers, neuroimaging biomarkers, and blood-based biomarkers help in providing quantitative data about the brain patterns and monitor the treatment response of the same.

The postpartum depression segment is the fastest-growing segment during the forecast period. These are common in women after giving birth. It involves feeling of exhaustion, fatigue, anxiety, and fluctuations in mood that can last for some months post-pregnancy. Biomarkers used for this disorder mostly include hormonal biomarkers or other biomarkers that aid in predicting risks associated with depression and suggest treatment or measures to reduce it. Further, biomarkers can help in personalized treatment selection for women post-pregnancy by identifying their response to different treatment interventions.

Global Depressive Disorders Biomarkers Market Segmentation: By Region

• North America

• Europe

• Asia Pacific

• Middle East and Africa

• South America

Based on market segmentation by region, North America occupies the highest share of the market. Due to the high prevalence of depression in the region and the rising demand for personalized medicine, there is an increase in demand for biomarkers for depressive disorder in the region. As per the National Institute of Mental Health, major depressive disorder affects 17.3 million adults in America, of which 7.1% are aged 18 and above. This has risen the demand for personalized medicine in the region that helps in diagnosing and treating depressive disorders as per the patient’s response to treatment intervention.

Asia-Pacific is the fastest-growing segment during the forecast period. Due to rising mental health awareness, and the presence of healthcare organizations, self-help group communities, and NGOs, there is an increase in demand for depressive disorder biomarkers in the region.

Global Depressive Disorders Biomarkers Market Key Players:

1. Ellipsis Health

2. Sonde Health

3. Kintsugi Health

4. Evocal Health

5. Alto Neuroscience

6. Biogen Inc

7. Sage Therapeutics

8. Abbott